Abstract

The specific aims of the Prevention and High Risk Studies Unit are to: 1) Establish an infrastructure to recruit and prospectively follow two independent populations of adolescents at risk for schizophrenia: one at genetic risk; the other at clinical risk. 2) Establish valid and reliable screening procedures for identifying high- risk populations of interest. 3) Develop and validate predictor profiles derived from the information collected from both the clinical and genetic at-risk subjects, including: A pre-psychosis predictor profile, consisting of both non-specific and attenuated schizophrenia-like clinical signs and symptoms as well as neurocognitive predictor deficits. A profile for pre-illness prevention consisting of early developmental abnormalities (especially in the neurocognitive, neuropsychological and physiological domains). 4) Pilot new pharmacological strategies for pre-psychosis preventive intervention.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH060575-03
Application #
6608286
Study Section
Special Emphasis Panel (ZMH1)
Project Start
2002-02-01
Project End
2003-01-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
$175,212
Indirect Cost

  Institution

Name
Long Island Jewish Medical Center
Department
Type
DUNS #
City
New Hyde Park
State
NY
Country
United States
Zip Code
11040

  Publications

DeRosse, Pamela; Nitzburg, George C; Kompancaril, Bernie et al. (2014) The relation between childhood maltreatment and psychosis in patients with schizophrenia and non-psychiatric controls. Schizophr Res 155:66-71
Wellington, Robin L; Bilder, Robert M; Napolitano, Barbara et al. (2013) Effects of age on prefrontal subregions and hippocampal volumes in young and middle-aged healthy humans. Hum Brain Mapp 34:2129-40
Kane, John M; Kishimoto, Taishiro; Correll, Christoph U (2013) Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 66:S37-41
Ardekani, Babak A; Tabesh, Ali; Sevy, Serge et al. (2011) Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteers. Hum Brain Mapp 32:1-9
Woerner, Margaret G; Correll, Christoph U; Alvir, Jose Ma J et al. (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 36:1738-46
Lencz, Todd; Robinson, Delbert G; Napolitano, Barbara et al. (2010) DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 20:569-72
Coscia, Denise M; Narr, Katherine L; Robinson, Delbert G et al. (2009) Volumetric and shape analysis of the thalamus in first-episode schizophrenia. Hum Brain Mapp 30:1236-45
Lencz, Todd; Lipsky, Robert H; DeRosse, Pamela et al. (2009) Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry 194:313-8
Szeszko, Philip R; Hodgkinson, Colin A; Robinson, Delbert G et al. (2008) DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol 79:103-10
Szeszko, Philip R; Robinson, Delbert G; Ashtari, Manzar et al. (2008) Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 33:976-84

Showing the most recent 10 out of 44 publications